Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine

Biologics: Targets and Therapy

Volumn 1, Issue 2, 2007, Pages 173-181

  Lasalvia Prisco, Eduardo ^a,d   Garcia Giralt, Emilio ^b   Cucchi, Silvia ^c   Vázquez, Jesús ^c,d   Robinson, Leonard ^a   Dalton, John ^a  

^a PharmaBlood Inc   (United States)

^b Centre De Cancerologie Hartmann   (France)

^c Department of Advanced Medical Treatments ^*  (Uruguay)

^d National Institute of Oncology   (Uruguay)

Author keywords

Autologous vaccine; Cancer immunotherapy; Cancer vaccine; Immunotherapy adjuvants; Ovarian cancer

Indexed keywords

EID: 79955845830     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Battaglia A, Ferrandina G, Buzzonetti A, et al. 2003. Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire. Immunology, 110:304-12.
2. Bryan CF, Eastman PJ, Conner JB, et al. 1993. Clinical utility of a lymph node normal range obtained by flow cytometry. Ann NY Acad Sci, 677:404-6.
3. Claessen AM, Valster H, Bril H, et al. 1989. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol Immunother, 28:131-5.
4. Claessen AM, Valster H, Bril H, et al. 1991. Tumor regression and induction of anti-tumor immunity by local chemotherapy of guinea-pigs bearing a line-10 hepatocarcinoma. Int J Cancer, 47:626-32.
5. Claessen AM, Bloemena E, Bril H, et al. 1992. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res, 52:2440-6.
6. Cochran AJ, Balda BR, Starz H, et al. 2000. The Augsburg Consensus: techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymph-adenectomy in cutaneous malignancies. Cancer, 89:236-41.
7. Cochran AJ, Huang RR, Lee J, et al. 2006. (September 2006 Article series: Tumour immunology). Tumour-induced immune modulation of sentinel lymph nodes. Nature Reviews Immunology, 6:659-70.
8. Disis ML, Bernhard H, Shiota FM, et al. 1996. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptidebased vaccines. Blood, 88:202-10.
9. Dranoff G. 2002. GM-CSF-based cancer vaccines. Immunol Rev, 188:147-54.
10. Garcia-Giralt E, Lasalvia-Prisco E, Cucchi S, et al. 2006. Ovarian cancer: autologous immunotherapy optimized by remote adjuvancy of a silicate induced granuloma. Proc. 42nd Annual Meeting Am Soc Clin Oncol (ASCO), Abstract 12515.
11. Lasalvia E, Cucchi S, Carlevaro T, et al. 1995. Anti-metastatic effect of a blood fraction from cancer patients. Proc 31st Annual Meeting of the Am Soc Clin Oncol (ASCO), Abstract 730.
12. Lasalvia E, Cucchi S, DeStefani E, et al. 1995. Autologous induction of tumoral fibrogenesis. Neoplasia, 12:5-10.
13. Lasalvia-Prisco E, Cucchi S, Vázquez J, et al. 2003. Antitumoral effect of a vaccination procedure with an Autologous hemoderivative. Cancer Biol Ther, 2:155-60.
14. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2006a. Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative. Med Oncol, 23:91-104.
15. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 2006b. Advanced breast cancer: antiprogressive immunotherapy using a thermostable autologous hemoderivative. Breast Cancer Research and Treatment, 100:149-60.
16. Leong SP, Enders-Zohr P, Zhou YM, et al. 1999. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother, 22:166-74.
17. Limpens J, Garssen J, Germeraad WT, et al. 1990. Enhancing effects of locally administered cytostatic drugs on T effector cell functions in mice. Int J Immunopharmacol, 12:77-88.
18. Limpens J, Garssen J, Scheper RJ. 1990. Local administration of cytostatic drugs enhances delayed-type hypersensitivity to Sendai virus in mice. Clin Immunol Immunopathol, 54:161-5.
19. Limpens J, Scheper RJ. 1991. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site. Clin Exp Immunol, 84:383-8.
20. Mariani G, Gipponi M, Moresco L, et al. 2002. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. Journal of Nuclear Medicine, 43:811-27.
21. Molenkamp BG, Vuylsteke RJCLM, van Leeuwen PAM, et al. 2005. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol, 167:1301-7.
22. National Cancer Institute, US. 2006. Common terminology criteria or adverse events v3.0 [online]. Accessed 23 October 2007. URL: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
23. Oken MM, Creech RH, Tormey DC, et al. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5:649-55.
24. Reali E, Canter D, Zeytin H, et al. 2005. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine, 23:2909-21.
25. Schag CC, Heinrich RL, Ganz PA. 1984. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncology, 2:187-93.
26. Scheper RJ, Vos A, de Groot J, et al. 1984. Evaluation of various cytostatic drugs as local immunotherapeutic agents. Invest New Drugs, 2:221-5.
27. Simons JW, Mikhak B, Chang JF, et al. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Research, 59:5160-8.
28. Tan BT, Limpens J, Koken M, et al. 1986. Local administration of various cytostatic drugs after subcutaneous immunization enhances delayed- type hypersensitivity reaction to sheep red blood cells in mice. Scand J Immunol, 23:605-9.
29. Therasse P, Arbuck SG, Einsenhauer EA, et al. 2000. New guideline to evaluate the response to treatment in solid tumors. European Organiza- tion for Research and Treatment Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst, 92:205-16.
30. high regulatory T cells are overrepresented in human meta- static melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol, 173:1444-53.
31. Vuylsteke RJCLM, van Leeuwen PAM, Meijer S, et al. 2002. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol, 161:19-26.
32. Wiseman CL, Kharazi AI, Kudinov YG, et al. 2001. Improvement in CA 19-9 strongly correlated with survival in pancreas patients treated with whole-cell tumor vaccine and subcutaneous GM-CSF. ASCO Annual Meeting. Proc Am Soc Clin Oncol, 20:Abstract 2640.
33. World Medical Association. 2004. Declaration of Helsinki [online]. Accessed 22 August 2007. URL: http://www.wma.net/e/policy/b3.htm
34. Yang A, Monken C, Lattime E. 2003. Intratumoral vaccination with vaccinia-expressed tumor antigen and granuloscyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Research, 63:6956-61.